Introduction: This study examines factors associated with erythropoiesis-stimulating agent
(ESA) hyporesponsiveness, the duration of ESA hyporesponsiveness, the frequency of new …

Introduction The optimal use of erythropoiesis stimulating agents (ESAs) to treat anemia in
end stage renal disease remains controversial due to reported associations with adverse …

Background Hemodialysis patients with erythropoiesis-stimulating agent (ESA)
hyporesponsiveness have been a topic of active research. However, there have been no …

Background Responsiveness to erythropoiesis-stimulating agents (ESAs) varies widely
among dialysis patients. ESA resistance has been associated with mortality in hemodialysis …

Background: Anemia resistant to erythropoietin stimulating agents (ESAs) is a risk factor for
all-cause mortality. Determining the etiologies of hyporesponsiveness may help overcome …

Hyporesponsiveness to erythropoiesis-stimulating agent therapy in dialysis patients is
poorly understood. Some studies report an improvement in the erythropoiesis-stimulating …

Background Some patients with chronic kidney disease do not respond adequately to
erythropoiesis-stimulating agent (ESA) treatment; these patients are referred to as ESA …

Abstract Background/Aims: Resistance to erythropoiesis-stimulating agent (ESA) is
associated with mortality in hemodialysis (HD) patients. Time-dependent variability of ESA …

Although there is no consensus as to a definition of erythropoiesis-stimulating agent (ESA)
resistance or hyporesponsiveness, ESA hyporesponsiveness often is described as a …

Angiotensin-converting enzyme (ACE) inhibitors may exacerbate anemia in patients with
chronic renal failure, as well as in dialysis patients. To better answer this question, a …